PLEK2 and IFI6, representing mesenchymal and immune-suppressive microenvironment, predicts resistance to neoadjuvant immunotherapy in esophageal squamous cell carcinoma

Jianhua Liu, Hao Chen, Guibin Qiao, Jia Tao Zhang, Shuaitong Zhang, Changbin Zhu, Yu Chen, Jiming Tang, Weiwei Li, Siyun Wang, Hongxia Tian, Zhihong Chen, Dong Ma*, Jie Tian*, Yi Long Wu*

*此作品的通讯作者

科研成果: 期刊稿件文章同行评审

11 引用 (Scopus)
Plum Print visual indicator of research metrics
  • Citations
    • Citation Indexes: 11
  • Captures
    • Readers: 9
see details

摘要

Background: Immunotherapy has largely improved clinical outcome of patients with esophageal squamous cell carcinoma (ESCC). However, a proportion of patients still fail to benefit. Thus, biomarkers predicting therapeutic resistance and underlying mechanism needs to be investigated. Methods: Transcriptomic profiling was applied in FFPE tissues from 103 ESCC patients, including surgical samples from 66 treatment-naïve patients with long-term follow-up, and endoscopic biopsies from 37 local advanced ESCC cases receiving neoadjuvant immunotherapy plus chemotherapy. Unsupervised clustering indicated an aggressive phenotype with mesenchymal character in 66 treatment-naïve samples. Univariant logistic regression was applied to identify candidate biomarkers potentially predicted resistance to neoadjuvant immunotherapy within the range of mesenchymal phenotype enriched genes. These biomarkers were further validated by immunohistochemistry. Putative mechanisms mediating immunotherapy resistance, as indicated by microenvironment and immune cell infiltration, were evaluated by transcriptomic data, and validated by multiplex immunofluorescence. Results: PLEK2 and IFI6, highly expressed in mesenchymal phenotype, were identified as novel biomarkers relating to non-MPR in neoadjuvant immunotherapy cohort [PLEK2high, OR (95% CI): 2.15 (1.07–4.33), P = 0.032; IFI6high, OR (95% CI): 2.21 (1.16–4.23), P = 0.016). PLEK2high and IFI6 high ESCC patients (versus low expressed patients) further exhibit higher chance of non-major pathological remissions (90%, P = 0.004) in neoadjuvant immunotherapy cohort and high mortality (78.9%, P = 0.05), poor prognosis in retrospective cohort. PLEK2high/IFI6high ESCC recapitulated mesenchymal phenotype, characterized by extracellular matrix composition and matrix remodeling. In addition, PLEK2high or IFI6high ESCC displayed an immune-unfavored microenvironment, represented by positive correlating with regulatory T cells, Helper 2 T cell as well as less infiltration of B cells, effector T cells and mast cells. Conclusions: PLEK2 and IFI6 was discovered of first time to identify a distinct ESCC subpopulation cannot be benefited from neoadjuvant immunotherapy and present a poor survival, which putatively associated with mesenchymal and immune-suppressive microenvironment.

源语言英语
页(从-至)881-893
页数13
期刊Cancer Immunology, Immunotherapy
72
4
DOI
出版状态已出版 - 4月 2023
已对外发布

指纹

探究 'PLEK2 and IFI6, representing mesenchymal and immune-suppressive microenvironment, predicts resistance to neoadjuvant immunotherapy in esophageal squamous cell carcinoma' 的科研主题。它们共同构成独一无二的指纹。

引用此

Liu, J., Chen, H., Qiao, G., Zhang, J. T., Zhang, S., Zhu, C., Chen, Y., Tang, J., Li, W., Wang, S., Tian, H., Chen, Z., Ma, D., Tian, J., & Wu, Y. L. (2023). PLEK2 and IFI6, representing mesenchymal and immune-suppressive microenvironment, predicts resistance to neoadjuvant immunotherapy in esophageal squamous cell carcinoma. Cancer Immunology, Immunotherapy, 72(4), 881-893. https://doi.org/10.1007/s00262-022-03288-0